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Abstract 
Background: Inflammatory bowel disease (IBD) is described as a relapsing condition with high morbidity and uncer-
tain complex pathogenesis. The association of Mycobacterium avium ssp. paratuberculosis (MAP) with Crohn’s disease 
(CD) in human has been debated for decades, however there is no confirmed data to verify such relations in Iran. The 
aim of this study was to investigate risk factors and a possible role of MAP in Iranian patients with CD.
Methods: Anti-MAP antibodies were detected in serum of IBD patients and subjects without IBD (nIBD) through 
ELISA; MAP DNA and viable MAP cells were identified in patients’ biopsies through nested PCR and direct culture 
methods, respectively. Principal component analysis (PCA) was used to investigate the risk factors in relation to IBD 
and MAP infection.
Results: Positivity for IS900 PCR was detected in 64% (n = 18) of CD, 33% (n = 10) of ulcerative colitis (UC) and 
9.7% (n = 6) of nIBD samples. Live MAP cells were isolated from biopsies of 2 CD patients only. Among 28 patients 
with CD, 46% (n = 13) and 39% (n = 11) were positive for antibodies against MAP3865c133–141 and MAP3865c125–133 
peptides, respectively, whereas much lower seroreactivity was detected in UC subjects accounting for 3% (n = 1) 
for MAP3865c133–141 and 16.7% (n = 5) for MAP3865c125–133. A high immune reactivity to MAP epitopes among CD 
patients was positively correlated with consumption of fast food meals and IBD familiarity. For both CD and UC, 
breastfeeding period and consumption of fruit/vegetables presented negative correlation with the presence of anti-
MAP antibodies.
Conclusions: This study provided evidences that high prevalence of MAP DNA and anti-MAP antibodies in CD 
patients is significantly associated with the development of CD. Despite the role of several factors contributing to IBD, 
the presence of MAP DNA and anti-MAP antibodies in Iranian CD patients highlights a possible transmission of MAP 
from animal-derived products to humans.
Keywords: Mycobacterium avium subsp. paratuberculosis, Inflammatory bowel disease, Crohn’s disease, ELISA, IS900 
nested PCR, Iran
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Gut Pathogens
*Correspondence:  mfeizabadi@tums.ac.ir 
1 Department of Microbiology, School of Medicine, Tehran University 
of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
Page 2 of 10Zamani et al. Gut Pathog  (2017) 9:1 
Background
Crohn’s disease (CD) and ulcerative colitis (UC) are 
the main types of inflammatory bowel disease (IBD) 
described as a relapsing condition with high morbidity 
and uncertain pathogenesis. In genetically susceptible 
persons cell-mediated immune responses to gastroin-
testinal bacteria seem to be involved in the etiology of 
these complex disorders [1–3]. The populations of North 
America and Europe are more affected by IBD than 
Asians [2], however the incidence of IBD has been rising 
in either Asia or developing countries [4]. Likewise, IBD 
has been diagnosed more recurrently in different parts of 
Iran in the last decades [5, 6]. In line with the high inci-
dence of IBD in American and European countries, most 
information regarding epidemiology, symptoms, risk 
factors and etiology of IBD are described based on the 
local populations [7, 8]. Although the etiology of IBD is 
largely complex and unknown, it is thought to be caused 
by a combination of genetic and environmental factors 
that affect the immune responses. Among the environ-
mental factors, Mycobacterium avium subsp. paratuber-
culosis (MAP)—a causative agent of Johne’s disease (JD) 
in domestic and wild ruminants, seems to be important 
in the pathogenesis of IBD, despite conflicting reports 
on its possible role in the disease. Some studies showed 
the involvement of MAP in CD in genetically susceptible 
individuals [9–11], whereas other reports could not con-
firm such findings [12–14].
There are limited data describing these complex dis-
orders in countries like Iran, while existence of MAP in 
industrial and traditional cattle farms, its isolation from 
feces, milk of dairy herds and from lymph nodes of goats 
along with undesirable consequences in ruminant live-
stock have been reported in various parts of the coun-
try [15–17]. During subclinical phase of JD MAP is shed 
through feces and milk, and can spread within the herd 
[18]. The ability of MAP to survive on vegetables fer-
tilized with contaminated manure, in water, raw meat, 
milk and dairy products is widely described. Therefore, 
infected animals are considered as an important source 
for transmission to humans [19–22]. Even though the 
association between MAP and Crohn’s disease highlight-
ing its putative triggering role has been intensely debated, 
there is no confirmation to verify similar relation in Iran 
[23]. Likewise, the knowledge regarding risk factors for 
IBD and rates of MAP infection in the country have not 
been cleared yet. Given the wide diffusion of the myco-
bacterium in domestic breeding and dairy industry in 
Iran, the need to study epidemiologic features and the 
impact of MAP on IBD is fundamental.
In this study, the presence of MAP in IBD patients and 
nIBD controls was investigated through nested-PCR, 
ELISA and culture methods. Additionally, correlation 
of MAP infection with IBD risk factors such as age, 
sex, clinical symptoms (diarrhea, constipation, bloody 
stool, low Hb and lose weight), breastfeeding and die-




In the present study, 120 specimens from IBD and non-
IBD (nIBD) patients were collected. The study popula-
tion was classified as follows: 28 patients affected by CD 
(14 males and 14 females; mean age 39.1  years, range 
18–64), 30 patients affected by UC (12 males and 18 
females; mean age 36.9 years, range 16–75) and 62 nIBD 
individuals (29 males and 33 females; mean age 50.35 
ears, range 18–76). The protocols were approved by Eth-
ics Committee of Tehran University of Medical Sciences 
and the informed consent was obtained in all cases. The 
diagnosis of CD was based on conventional clinical, 
endoscopic, and histologic criteria and disease activity 
was assessed with Crohn’s Disease Activity Index (CDAI) 
[24, 25]. Biopsy samples were obtained from the affected 
colon, terminal ileum and rectum of patients upon colo-
noscopy. UC patients presented typical features such as 
active colitis with ulceration and inflammation of the 
mucosa with special distribution. The selected patients 
were newly diagnosed for IBD and have not undergone 
antibiotic treatment for at least 3 months. nIBD controls 
were selected among individuals subjected to screening 
surgery due to other nIBD-associated conditions like 
abdominal pain or an alteration in bowel habit. No colo-
noscopic or histological abnormalities of the ileum or 
colon were observed in this group. Any kind of clinical 
and/or histopathological diagnosis of IBD was excluded 
and the biopsies were obtained in the same way as did 
for patients with IBD/CD or UC. No history of antibiotic 
therapy during 3  months prior to sampling is recorded. 
Additionally, 2  ml of blood samples collected from all 
subjects were transferred into clot activator tubes and 
centrifuged for 10 min at 400×g (2000 rpm) in order to 
separate the serum for further ELISA tests. The sera were 
preserved at −20 °C until use.
Bacterial culture of gut specimens
All biopsy samples were resuspended in 15 ml of freshly 
prepared sterile 0.75% (w/v) hexadecylpyridinium chlo-
ride (HPC; Merck, Darmstadt, Germany) and kept at 
room temperature (25  °C) for 18 h. After decontamina-
tion samples were centrifuged at 3000×g for 20 min and 
the sediments were resuspended in 5 ml PBS. Equal vol-
ume of each decontaminated sample was inoculated into 
Herrold’s egg yolk medium (HEY) containing mycobactin 
J (MJ) and incubated at 37 °C for up to 6 months.
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DNA extraction
DNA was extracted directly from biopsies using RTP® 
Mycobacteria Kit (Invitek, Berlin, Germany) and stored 
at −20 °C for nested-PCR assays.
IS900 specific nested PCR and sequencing
MAP target gene IS900 was amplified using nested PCR 
primers [L/AV] L (L1: 5′-CTT TCT TGA AGG GTG 
TTC GG-3′ and L2: 5′-ACG TGA CCT CGC CTC CAT-
3′) and AV (AV1: 5′-ATG TGG TTG CTG TGT TGG 
ATG G-3′ and AV2: 5′-CCG CCG CAA TCA ACT CCA 
G-3′) according to protocols described by other authors 
[26]. Then, specificity of the amplicons was checked by 
sequencing.
ELISA
MAP3865c125–133 (MIAVALAGL) and MAP3865c133–141 
(LAANFVVAL) peptides were synthesized at >90% 
purity (GL Biochem). The peptides were resuspended 
in 10  mM of dimethyl sulfoxide (DMSO) and kept in 
single-use aliquots at −70  °C. Indirect enzyme-linked 
immunosorbent assay (ELISA) was used to detect anti-
MAP3865c133–141 specific antibodies (Abs). 10  µg/ml of 
MAP3865c peptides diluted in 0.05 M carbonate–bicar-
bonate buffer (Sigma) used for coating of 96-well Nunc 
immunoplates. Phosphate-buffered saline (PBS) contain-
ing 0.05% Tween-20 (PBS-T) was used as washing buffer, 
modified by adding 5% non-fat dried milk (Sigma) for 
blocking of nonspecific binding sites. All steps were per-
formed as previously reported [27]. VersaTunable MAX 
microplate reader was applied for determination of opti-
cal density (OD) at the wavelength of 405 nm.
Risk factor variables
IBD risk factors analyzed in correlation with MAP infec-
tion in the present study population [28] were selected 
based on demographic data (age, sex, geographical pro-
venience), clinical symptoms (diarrhea, constipation, 
bloody stool, low Hb and lose weight), ongoing therapy, 
disease familiarity, period of breastfeeding, smoking and 
dietary habits (consumption of raw and pasteurized milk, 
fast food meals, green tea, fruit and vegetables).
Statistical analysis
The cut-off values for sample positivity were calcu-
lated based on the receiver operating characteristics 
(ROC) curve with specificity established at 95%. In case 
of CD patients, cut-off points equaled 0.45  U/ml for 
MAP3865c133–141 and 0.73  U/ml for MAP3865c125–133. 
For UC subjects, the threshold values were estab-
lished at 0.50 and 0.73  U/ml for MAP3865c133–141 and 
MAP3865c125–133 epitopes, respectively. The same nIBD 
individuals were used as a reference for the analysis 
of both disease groups. Statistical significance of the 
data was determined through the student’s t test (95% 
CI) employing GraphPad Prism software (version 6.02, 
La Jolla, USA). Variables correlated with the positivity 
for MAP peptides were identified through the princi-
pal component analysis using XLSTAT (version 2015.1, 
Addinsoft, France). The cut-off for variable loadings 
describing the degree of correlation between variables 
and principal components was arbitrarily set at ≥0.45 as 
previously described [29], with higher values considered 
major contributors.
Results
Among 28 CD patients, 46% (n =  13) were positive for 
MAP3865c133–141 and 39% (n = 11) for MAP3865c125–133 
peptides (p < 0.0001 in both cases), whereas much lower 
seroreactivity was detected among UC subjects account-
ing for 3% (n = 1) for MAP3865c133–141 and 16.7% (n = 5) 
for MAP3865c125–133 (p  <  0.69 and p  <  0.0067, respec-
tively). nIBD displayed anti-MAP positivity of 5% (n = 3) 
for MAP3865c133–141 and 6% (n = 4) for MAP3865c125–133 
epitopes when the analysis was statistically significant 
(Fig. 1).
The peptides highly correlated in CD patients 
(R2  =  0.48; Fig.  2) characterized by positivity to both 
antigens in 60% of individuals bearing anti-MAP Abs. 
This correlation was weaker for UC subjects (R2 = 0.31). 
Upon sex-related analysis, Abs reactivity against any of 
the MAP peptides among males and females was equal 
in CD patients and nIBD but showed 2:3 ratio in UC 
subjects.
MAP was cultured in Herrold’s egg medium plus myco-
bactin J from biopsies of two CD patients, both of them 
were positive in ELISA and PCR tests.
MAP specific IS900 gene was detected by nested PCR 
in 64% of CD (n  =  18), 33% of UC (n  =  10) and 9.7% 
of nIBD (n  =  6) samples; the IS900 positivity was not 
reflected by the presence of anti-MAP Abs in 11 cases 
among patients only, however 6 of them showed high 
Abs titers (Table 1). All the biopsy specimens with posi-
tive MAP DNA detection were taken from the terminal 
ileum.
Multivariate analysis revealed several variables among 
demographic data, clinical history and nutritional habits 
correlated with MAP epitopes. Following the Keiser–
Guttman criterion, ten principal components with 
eigenvectors ≥1.0 were identified for CD patients and 
accounted for 70.3% of the total variation, however vari-
able loadings exceeding the established cut-off were not 
found in the last principal component (Table 2). For prin-
cipal component 1 described by 19% of the variation, 12 
variables showed loadings higher compared to the estab-
lished threshold, translated into a strong relationship 
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between immune reactivity to the MAP peptides, pres-
ence of MAP DNA, IBD history within family, Asacol 
treatment, consumption of fast food meals and clinical 
symptoms such as bloody stool, low Hb and weight loss; 
an inverse association was observed among variables 
related to age, consumption of fruit and vegetables and 
duration of breastfeeding period. Three values reached 
the cut-off point for principal component 2 accounting 
for 8.5% of the total variation and included familiarity of 
cancer, consumption and pasteurization of milk. Princi-
pal components from 3 to 9 were described each by only 
one variable.
For UC patients, nine principal components were 
identified with the cumulative variation of 67.6% and 
loadings higher than ≥1.0 observed in the first eight 
components. Principal component 1 was explained by 
18% of the total variation and 9 variables including reac-
tivity against MAP3865c125–133 only, IBD history, Mesa-
lamine treatment, clinical symptoms characterized by 
diarrhea, bloody stool and weight loss. Age, consump-
tion of fruit and vegetables as well as breastfeeding 
period also presented a strong relationship but in the 
opposite way. Correlation between the two MAP pep-
tides was characteristic for principal component 2 
described by 9.5% of the total variation and, as expected, 
presented an inverse relationship with patients’ gender. 
Of note, consumption of green tea was negatively asso-
ciated with anti-MAP Abs positivity, clinical symptoms 
and history of IBD and diabetes which may be due to its 
antibacterial effect.
Based on several reports associating MAP to diet and 
its possible transmission with contaminated food, we 
restricted our analysis to variables describing patients’ 
nutritional habits, geographical provenience and dura-
tion of breastfeeding. Figure  3 illustrates bi-plot distri-
butions of variables and Abs positivity to MAP epitopes 
in both patients groups and nIBD. A strong relationship 
was observed between MAP antigens and frequency of 
fast food meals consumption, mirrored by a higher reac-
tivity to the peptides. This relationship was explained by 
42% of the total variation for CD patients and 35% for UC 
subjects for whom the fast food variable described prin-
ciple component 3. In both cases, milk pasteurization 
was not negatively correlated with positivity to anti-MAP 
Fig. 1 Prevalence of Abs against MAP epitopes in CD, UC and nIBD subjects. Distribution of Abs values based on the statistical analyses was 
performed separately for MAP3865c133–141 (a, b) and MAP3865c125–133 (c, d) with respect to disease. The dotted lines indicate the cut-off for positivity 
relative to each assay established through ROC analysis. The percentage of anti-MAP reactive subjects, statistically significant p values (CI 95%) and 
AUC are reported on top of each distribution. Horizontal bars specific for CD, UC and nIBD groups represent means
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Abs pointing at the ability of the mycobacterium to sur-
vive this process. Duration of breastfeeding showed an 
inverse correlation indicating its protective role against 
MAP infection. The prevalence of women among UC 
patients reactive to MAP epitopes was explained by prin-
cipal component 1.
Fig. 2 Correlation between Abs recognizing MAP3865c133–141 and MAP3865c125–133 peptides in CD, UC and nIBD subjects. Distributions corre-
sponding to CD (a) and UC (b) were analyzed with the same nIBD group. Circles correspond to patients or nIBD positive to anti-MAP Ab. Thresholds 
for positivity calculated by ROC analysis and specific to each assay are indicated by the dotted lines. R2 and p values relative to each correlation are 
reposted in the top-left corners
Table 1 Prevalence of anti-MAP Abs and MAP DNA among CD, UC and nIBD patients
Numbers with the relative percentages of subjects positive (Abs+) and negative (Abs−) to MAP3865c133–141 (MAP1) and MAP3865c125–133 (MAP2) peptides. Analogous 










CD 13 (46%) 15 (54%) 11 (39%) 17 (61%) 18 (64%) 10 (36%)
UC 1 (3%) 29 (97%) 5 (16.7%) 25 (83.3%) 10 (33%) 20 (67%)
nIBD 3 (5%) 59 (95%) 4 (6%) 58 (94%) 7 (9.7%) 55 (90.3%)
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Discussion
CD and UC mainly involve the gastrointestinal tract. 
Individuals with susceptible gene loci exposed to cer-
tain environmental factors undergo the activation of 
immune responses to a variety of species composing the 
gut microbiota that results in the development of CD 
or UC [30]. Similar to other developing countries, the 
rate of UC and CD is increasing in Iran [4]. This study 
described a high prevalence of MAP DNA in biopsies 
of CD patients. Among CD individuals, the positivity 
for IS900 PCR—a specific repeated insertion sequence 
in MAP genome, was characterized by high statistical 
significance suggesting a possible role of MAP in trig-
gering CD, whereas lower IS900 PCR detection rates 
were observed in UC patients. Moreover, most of the 
samples in the control group were negative for MAP 
DNA. Products of the positive samples were sequenced 
and further confirmed the presence of MAP. Our results 
point at the isolation of MAP from livestock and dairy 
products reported in Iran and suggest a possible expo-
sure to the microorganism. Infected animals with sub-
clinical symptoms of JD, in particular dairy cattle, 
shed MAP from feces and may increase the risk of its 
transmission to humans [16, 17]. The absence of MAP 
DNA in some CD patients may be explained by the fact 
that different bacterial populations are responsible for 
CD in distinct intestinal regions. The positive results 
obtained by PCR did not match with those of ELISA in 
11 patients suggesting that sensitivity of ELISA test was 
lower than PCR, as described in a previous study [31]. 
Additionally, history of IBD treatment may lower anti-
MAP Abs titers; to note is the fact that nIBD individuals 
showed a complete coincidence of serological response 
and molecular results. Several reports demonstrated 
that MAP can be more commonly detected from CD 
than UC or healthy populations [32–34]. Conversely, 
some studies have not found an association between 
MAP detection and IBD [35, 36].
Following 6  months of incubation in culture media, 
only two samples with positive ELISA and PCR results 
simultaneously showed colonies of MAP; poor culture 
outcomes may be due to the fastidious nature of the 
mycobacterium that is hardly detected by conventional 
microbiological techniques [37].
Table 2 Loadings of variables most related to each principal component representative for CD patients and nIBD
Nine principal components with major contribution of each variable have been included. Italic values denote loadings ≥0.45. The table includes only variables 
exceeding the established threshold, relative to demographics, clinical history and nutritional habits of the selected participants. Percentage of the total variation is 
given for each principal component 
Variables Principal components
PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9
Total variation (%) 18.89 8.57 7.9 7.26 5.7 5.15 4.65 4.56 4.08
MAP3865c133–141 0.65 −0.15 −0.32 −0.28 0.15 0.17 −0.17 0.04 0.01
MAP3865c125–133 0.74 −0.21 −0.28 −0.28 0.01 0.21 −0.19 −0.05 −0.02
MAP DNA 0.74 0.10 −0.21 −0.10 0.12 0.03 −0.20 0.15 −0.03
Age −0.66 0.28 −0.32 −0.03 −0.29 0.06 −0.2 −0.11 0.15
Gender −0.15 −0.09 −0.5 0.63 0.24 −0.06 −0.27 0.03 0.06
City 0.06 −0.23 −0.18 −0.25 −0.25 −0.31 −0.14 0.48 −0.31
IBD history 0.49 0.28 0.25 0.38 −0.39 0.04 −0.01 −0.02 0.03
Cancer history 0.02 0.46 −0.36 −0.11 0.18 0.01 0.35 0.1 −0.04
Diabetes history 0.21 0.38 −0.46 −0.05 −0.19 −0.24 0.27 0.2 0.01
Asacol treatment 0.48 0.13 0.32 0.12 −0.08 0.52 −0.12 0.19 0.07
Diarrhea 0.24 0.29 −0.09 −0.24 0.49 −0.15 0.21 −0.14 0.09
Constipation −0.07 −0.25 −0.22 0.32 −0.06 0.19 0.46 −0.38 0.01
Bloody stool 0.47 −0.37 −0.04 0.13 −0.2 −0.21 0.21 −0.18 −0.1
Low Hb 0.54 −0.17 −0.27 0.2 −0.08 0.14 0.16 −0.33 −0.26
Weight loss 0.52 0.33 0.01 0.21 0.32 −0.26 0.07 0.17 −0.04
Smoke 0.22 0.4 −0.13 −0.28 −0.02 −0.01 0.08 −0.19 0.52
Milk consumption 0.15 −0.45 0.07 0.15 −0.23 0.29 0.11 0.16 0.28
Pasteurized milk −0.15 0.52 0.15 0.3 0.19 0.36 −0.29 −0.26 −0.02
Fruit/vegetables −0.57 −0.06 −0.13 −0.15 0.35 −0.08 −0.12 −0.15 −0.05
Breastfeeding duration −0.56 0.03 −0.28 −0.36 0.02 0.15 0.03 −0.21 −0.15
Fast food 0.48 0.06 0.25 0.11 0.46 0.00 −0.04 0.11 0.05
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Fig. 3 Principal component analysis of variables with potential influence on MAP transmission and positivity to MAP3865c133–141/MAP3865c125–133 
peptides. Bi-plots show correlation between the analyzed epitopes and variables relative to personal dietary history, geographical provenience and 
gender in CD patients (a), UC subjects (b) and nIBD used for both analyses. Samples positive to anti-MAP Abs are represented by squares whereas 
those negative by circles; all variables are described by labels and their position is indicated by triangles. The distribution illustrates only PC1 and PC2 
correlations
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In CD patients, the positivity rates for MAP3865c 
peptides were higher compared to UC subjects and 
nIBD group. As the specificity of the bacterial peptides 
applied in our ELISA method achieves a 100% for MAP, 
we can certainly declare that ELISA-positive subjects 
were exposed to MAP and not to other environmental 
mycobacteria. In some previous studies, the association 
between anti-MAP peptides and autoimmune diseases 
like CD, type 1 diabetes, multiple sclerosis (MS) and 
Hashimoto’s thyroiditis have been reported [38–41].
Detection of increased seroreactivity against MAP in 
few control samples may be caused by environmental 
exposure to the extracellular form of MAP; however, pro-
duction of preservative Abs against MAP in these sub-
jects potentially prevents the progression to CD [22].
In this study, results of nested PCR and ELISA showed 
a significant association of positivity to antibodies 
against MAP and the presence of MAP DNA in a group 
of Iranian CD patients. A similar association has been 
described in several studies including different popu-
lations. Culture was positive from biopsies of two CD 
patients only. Nevertheless, MAP DNA was also detected 
in UC and nIBD controls with a lower prevalence in com-
parison to CD subjects. These data permit to hypoth-
esize that MAP may not be the only etiological factor, but 
probably a predisposing element in interplay with other 
determinants.
In some clinical trials, anti-mycobacterial therapy 
including clarithromycin, rifabutin and/or clofazimine 
had positive effects for the treatment of CD and MS 
patients. If the role of MAP is confirmed, we can recom-
mend prescription of anti-mycobacterial therapy that 
may result more effective in practice for Iranian IBD 
patients under treatment of CD [42].
A high immune reactivity to MAP epitopes among CD 
patients was positively correlated with the consumption 
of fast food meals, weight loss, milk pasteurization and 
IBD familiarity. For both CD and UC, factors such as age, 
breastfeeding period and consumption of fruit/vegeta-
bles presented negative correlation with the presence of 
anti-MAP antibodies. The results of our study showed 
that breastfeeding influences MAP colonization and IBD 
onset in adulthood. According to some authors, breast-
feeding has a protective effect on IBD development, 
especially when continued for at least 12 months [43, 44]. 
The beneficial role of breastfeeding most likely relates to 
changes in gut microbial community in stool of breast-
fed infants compared to those fed with milk formula [43]. 
Also, according to previous studies, dysbiosis of the fecal 
microbiota can be linked with MAP infection [45]. Such 
changes in gut microbial community are correlated as 
well with the increasing rate of IBD; particularly, frequent 
consumption of fast food meals, fatty acids and reduced 
intake of fruit and vegetables have been associated with 
the disease development [43–46]. Moreover, polyphenols 
contained in fruit, and at high concentrations in green 
tea, can help to increase the levels of antioxidants and 
attenuate severity of colitis in the analogous way to sul-
fasalazine, reducing the rate of IBD in Iranians [43, 47]. 
The result of this study proposes that pasteurized milk 
would need to be considered as a weak transmission vec-
tor confirming the previous report [48] and is in line with 
other reports. Data regarding the intake of dairy products 
were not available for the enrolled patients; consumption 
of processed cheese has been significantly associated 
with CD and its evaluation in Iranian cohort would be 
worthwhile [49].
Conclusions
Despite the role of multiple factors in progression to IBD, 
detection of anti-MAP antibodies and MAP DNA together 
with two cases of isolation of viable MAP cells from Ira-
nian CD patients highlights the importance of possible 
sources of exposure to the mycobacterium and routes of 
its transmission from animal products to humans. Yet, 
MAP may be a predisposing factor according to a high 
significance of the obtained data; additional information 
about the genetic background of patients and role of other 
bacteria and environmental factors are needed for a com-
plete picture. If MAP role in CD is approved, it can be a 
warning for health care organizations to improve hygiene 
controlling systems in livestock farms and dairy indus-
tries towards reduction of MAP transmission to humans. 
Also, for these complex disorders, the optimal applica-
tion of antibiotics indicated for a defined patient group 
will depend on a clear determination of microbial agents 
involved in the pathogenesis. The present study suggests 
that anti-mycobacterial therapy should be more effective 
in practice. Enrollment of more numerous patient groups 
from various geographical regions of Iran may further elu-
cidate the role of MAP in IBD.
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